Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 602 participants.

Also called NCT04981041

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 602 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04981041
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria, Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04981041. Randomized; single masking; primary purpose treatment. Start 2021-12-16 (actual); primary completion 2026-05-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
Acronym
EPIDAURUS
Condition
Acute Coronary Syndrome
Intervention (Drug)
Prasugrel or Ticagrelor
Intervention (Drug)
Clopidogrel
Lead sponsor
Ludwig-Maximilians - University of Munich (class: other)

Record details

Record id
cardio:ct-nct04981041
Content hash
9285000bf7dffabc0172edbc07259656f3fcbf5d41baa2a5f86d01835f31e69c